Numbers needed to decide

Journal of the National Cancer Institute

Volumn 101, Issue 17, 2009, Pages 1163-1165

  Woloshin, Steven ^a,b   Schwartz, Lisa M ^a,b  

^a DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER SCREENING; EDITORIAL; HUMAN; MAMMOGRAPHY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER;

ANXIETY; BREAST NEOPLASMS; DECISION MAKING; EARLY DETECTION OF CANCER; EUROPE; FALSE POSITIVE REACTIONS; FEAR; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MAMMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNNECESSARY PROCEDURES;

EID: 69949158983     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp263     Document Type: Editorial

References (17)

1. Burke W, Olsen AH, Pinsky LE, Reynold SE, Press NE. Misleading presentations of breast cancer in popular magazines. Eff Clin Pract. 2001;4:58-64.
2. PSA screening test for prostate cancer: An interview with Otis Brawley, MD, by Maryann Napoli. Center for Medical Consumers. http://medical consumers.org/2003/05/01/psa-screening-test-for-prostate-cancer/. Accessed July 14, 2009.
3. 3. Woloshin S, Schwartz L, Welch H. The risk of death by age, sex, and smoking status in the United States: putting health risks in context. J Natl Cancer Inst. 2008;100(12):845-853. Erratum in: J Natl Cancer Inst. 2008;100(16):1133. (Pubitemid 351881950)
4. 4. Jørgensen K, Gøtzsche P. Content of invitations for publicly funded screening mammography. BMJ. 2006;332(7540):538-541. (Pubitemid 44364373)
5. Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst. 2009;xx(xx): XXX-XXX.
6. The American Association for Public Opinion Research. Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. 4th ed. Lenexa, KS: AAPOR; 2006.
7. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2006;(4):CD001877.
8. 8. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338(16):1089-1096. (Pubitemid 28227478)
9. Solveig H, Vacek P, Skelly J, Weaver D, Geller B. Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst. 2008;100(15):1082-1091.
10. 10. Zackrisson S, Andersson I, Janzon L, Manjer J, Game P. Rate of overdiagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ. 2006;332(7543):689-692. (Pubitemid 44365683)
11. Schroder F, Hugosson J, Roobol M, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13): 1320-1328.
12. Andriole G, Grabb R III, Buys S, et al. Mortality results from a randomized prostate-cancer trial. N Engl J Med. 2009;360(13):1310-1319.
13. Croswell J, Kramer B, Kreimer A, et al. Cumulative incidence of falsepositive results in repeated, multimodal cancer screening. Ann Fam Med. 2009;7(3):212-222.
14. Welch HG. Should I be tested for cancer? Berkeley, CA: University of California Press, 2003.
15. Woloshin S, Schwartz LM, Welch HG. Know Your Chances: Understanding Health Statistics. Berkeley, CA: University of California Press; 2008.
16. Schwartz L, Woloshin S, Welch H. Using a drug facts box to communicate drug benefits and harms. Ann Intern Med. 2009;150(8):516-527.
17. Baum M, McCartney M, Thornton H, et al. Breast cancer screening peril: negative consequences of the breast screening programme. The Times (London), http://www.timesonline.co.uk/tol/comment/letters/article57616 50.ece.Accessed July 9, 2009.